BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
One Percent Rule Checklist For Safer Forex Trading Risk 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
British drugmaker AstraZeneca Plc announced that Shenzhen Kangtai Biological Products would produce its potential COVID-19 vaccine in mainland China.
Under the agreement, Shenzhen Kangtai will ensure that it produces annually at least 100 million doses of AZD1222, an experimental shot that AstraZeneca co-developed with Oxford University researchers.
The deal highlights Astra's frontrunner position in delivering a COVD-19 vaccine, considering that Chinese ventures lead at least eight of the 26 global vaccine development projects.
The Shenzhen-based company, one of China's top vaccine makers, revealed via WeChat that it is mandated by the agreement to have the production capacity for at least 200 million doses by the end of 2021.
AstraZeneca said it would also explore cooperation with Shenzhen Kangtai in other markets.
The British pharmaceutical firm has signed manufacturing deals in the US, UK, South Korea, and Brazil for over two billion doses of the vaccine.
Other tie-ups between Chinese and Western players are between Fosun and Germany's BioNTech and Beijing Advaccine Biotechnology with Inovio Pharma.
Shenzhen Kangtai's main products are vaccines for Hepatitis B, flu and measles, and rubella.
